Page 302 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

276 Elizabeth J. Brant, Julie G. McGregor, J. Charles Jennette et al.
[78] Hogan SL, Nachman PH, Wilkman AS, et al. Prognostic markers in patients with

antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and
glomerulonephritis. J. Am. Soc. Nephrol. 1996; 7:23-32.
[79] Watanabe K, Tani Y, Kimura H, et al. Clinical outcomes of Japanese MPO-ANCA-
related nephritis: significance of initial renal death for survival. Intern. Med. 2012; 51:
1969-1976.
[80] De Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and
myeloperoxidase ANCA-associated systemic vasculitis. Clin. J. Am. Soc. Nephrol.
2013; 8: 1709-1717.
[81] Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in
antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern.
Med. 2005; 143:621-631.
[82] Lee T, Gasim A, Derebail VK, et al. Predictors of Treatment Outcomes in ANCA-
Associated Vasculitis with Severe Kidney Failure. Clin. J. Am. Soc. Nephrol. 2014 Feb
27 [Epub ahead of print].
[83] Socias R, James DG, Pozniak A. Wegener and Wegener's granulomatosis. Thorax
1987; 42: 920-921.

Complimentary Contributor Copy